Clinical Report: Making Pediatric Leukemia Testing Accessible
Overview
Jeremy Wang describes a low-cost, portable nanopore long-read transcriptome sequencing approach intended to provide multimodal molecular diagnostic information for pediatric leukemia. In the reported demonstration, up to 12 samples were multiplexed per flow cell, with estimated consumables costs of about $100 per case; validation against standard-of-care diagnostics remains ongoing.
Background
Molecular classification can inform pediatric leukemia diagnosis, risk stratification, and treatment selection. Current diagnostic workups may involve multiple methods, including flow cytometry, karyotyping, FISH, and molecular tests, requiring infrastructure, equipment, and expertise. The source reports that these requirements can limit access in low-resource settings, including low- and middle-income countries, where most pediatric cancer patients are seen. Contemporary guidance also emphasizes resolving biologically defined leukemia subtypes using appropriate molecular assays.
Data Highlights
| Measure | Reported detail |
|---|---|
| Sequencer | Oxford Nanopore Technologies MinION; approximately $5,000 USD |
| Multiplexing | Up to 12 samples per flow cell |
| Flow-cell cost | Approximately $1,000 USD |
| Estimated consumables cost | Approximately $100 USD per case |
| Validation status | Ongoing; the next step described is assessment of concordance or non-inferiority versus standard-of-care diagnostics |
Key Findings
- The interview describes conventional pediatric leukemia molecular testing as a series of potentially time-consuming and expensive procedures, including flow cytometry, karyotyping, FISH, and molecular tests.
- Wang identifies equipment cost, infrastructure, and operational expertise as barriers to comprehensive testing, particularly in low-resource settings.
- The proposed approach uses long-read nanopore sequencing and computational tools intended to support multimodal leukemia diagnostics at low sequencing depth.
- The reported MinION demonstration multiplexed up to 12 samples on a flow cell costing approximately $1,000 USD, with estimated consumables costs of around $100 USD per case.
- The interview states that computational tools were developed to enable analysis without dedicated bioinformatics personnel; validation is continuing at the University of North Carolina and with international collaborators.
- The NCCN pediatric ALL guideline source listed in the web research context describes multiple biologically defined B-ALL entities requiring resolution with contemporary assays, illustrating the molecular breadth relevant to classification.
Clinical Implications
The approach is being evaluated as a way to make molecular diagnostic information more accessible where equipment and specialist expertise are limited. The interview identifies comparison with standard-of-care diagnostics, including assessment of concordance or non-inferiority, as a necessary next validation step before wider adoption.
Conclusion
Portable long-read sequencing with simplified computational analysis is presented as a potential lower-cost route to comprehensive pediatric leukemia diagnostics. Its diagnostic performance relative to standard methods remains under validation.
Related Resources & Content
- Jeremy Wang, interview following AMP 2026 Meeting & Expo -- Making Pediatric Leukemia Testing Accessible
- Raul C. Ribeiro and Valentino Conter, ASCO Publications, 2023 -- Optimizing Pediatric Leukemia Care in Countries With Limited Resources
- NCCN, JNCCN, 2025 -- NCCN Clinical Practice Guidelines in Oncology
- ASCO Publications — Optimizing Blinatumomab Access for Low- and Middle-Income Countries: Feasibility of a Shortened, Vial-Sharing, Outpatient Approach for Pediatric ALL
- ASCO Publications — Optimizing Pediatric Leukemia Care in Countries With Limited Resources
- ASCO Publications — Aligning EHR Data for Pediatric Leukemia With Standard Protocol Therapy
- NCCN Clinical Practice Guidelines in Oncology
- Optimizing Pediatric Leukemia Care in Countries With Limited Resources
- NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
- Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children
- Benchmarking standard-of-care and emerging genomic approaches to enhance diagnosis in pediatric acute lymphoblastic leukemia
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

About the Author(s)
Helen Bristow
Combining my dual backgrounds in science and communications to bring you compelling content in your speciality.